DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/28wbzl/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Acasti Pharma Inc.
- Allergan Plc
- Alnylam Pharmaceuticals, Inc.
- Arisaph Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- BASF SE
- Cardax Pharmaceuticals, Inc.
- Catabasis Pharmaceuticals, Inc.
- CymaBay Therapeutics, Inc.
- Daiichi Sankyo Company, Limited
- Essentialis, Inc.
- Isis Pharmaceuticals, Inc.
- Jeil Pharmaceutical Co., Ltd.
- Michigan Life Therapeutics, LLC
- Novartis AG
- Pharmena SA
- Tekmira Pharmaceuticals Corp.
Thetis Pharmaceuticals LLC
For more information visit http://www.researchandmarkets.com/research/28wbzl/high